$DNA Q3 2022 Earnings Report

$DNA Long

Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications. In 2020, Ginkgo partnered with Moderna to optimize the production of its COVID-19 vaccines. And last month, in the company's largest cell engineering deal to date, Ginkgo Bioworks signed an agreement with Bayer to assist the development of its agricultural medicines. Also last month, Ginkgo Bioworks announced the acquisition of another biotech company Zymergen, whose platform will add to Ginkgo's existing capabilities. The deal is expected to be complete by early 2023. All of these could be great news to investors as to what the company has lined up in the future. Adding more, this company seems to have a huge backing as their stock has never gone down after a report, even after horrible results. For example last quarter, they reported an EPS that was lower by 1400% compared to last year and it still wasn’t able to beat the estimates. However, their stock still jumped by 12%. Another factor to consider is that Zymergen posted a $68 million operating loss in the first quarter. Ginkgo's already losing money on its own, as a massive surge in both its stock-based compensation and its research and development spending outpaces its revenue growth. The company posted a net loss of nearly $2.4 billion over the trailing 12 months, and burned through a smaller but still significant $263.8 million in free cash in the same period. To avoid an even bigger impact on operating costs, Ginkgo will have to substantially restructure Zymergen's organization while shoring up its own. This will be an incredibly hard task as inflation is also at an all-time high. Furthermore, Ginkgo is down around 60% from its highs posted late last year. However, that doesn’t mean the company is financially struggling. In the latest available earnings, the company reported year-over-year revenue growth of 282% for Q1 of this year. In its highest recorded quarterly revenue to date, the company brought in sales of $168 million, up from $44 million in Q1 2021. This revenue growth was largely possible by the 11 new cell programs added to its foundry platform in the first quarter, a 175% increase year over year. The company's management also raised its expected total revenue range for the year by 15%, to $375 million-$390 million. And Ginkgo also has a $1.5 billion cash balance which will not only keep it safe financially but also help fund further company developments. This includes investing back into the company's core technology platform as well as other possible acquisitions. Disadvantages: Considering the fact that this is a penny stock, its volatility will be much less and will have much higher % changes. They have also recently acquired a new company that is losing money heavily which could affect their revenue.

Stock price history: Last week +10% Last month +17% Last 6 months -36% Last year -64% Initial reaction: Short Researched reaction: Long Debt: 23M Revenue: 300M Recent purchases: Endurance Wealth Management Inc. raised its stake in shares of Ginkgo Bioworks by 100.0% in the first quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company’s stock valued at $40,000 after acquiring an additional 5,000 shares during the period. Financial Consulate Inc. bought a new position in shares of Ginkgo Bioworks in the first quarter worth about $40,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Ginkgo Bioworks in the first quarter worth about $54,000. Cowen Prime Advisors LLC bought a new position in shares of Ginkgo Bioworks in the first quarter worth about $60,000. Finally, Formidable Asset Management LLC bought a new position in shares of Ginkgo Bioworks in the first quarter worth about $62,000. Amount of estimates missed since last year: 3/3 % owned by hedge funds: 47% Top 10 Owners of Ginkgo Bioworks Holdings Inc Stockholder Stake Shares owned Total value ($) Shares bought / sold Total change Baillie Gifford & Co. 18.70 % 205,327,78 6 587,237,468 +37,575,106 +22.40% ARK Investment Management LLC 7.96% 87,358,057 249,844,043 +22,824,417 +35.37% The Vanguard Group, Inc. 7.82% 85,852,665 245,538,622 +56,949,240 +197.03 % Anchorage Capital Group LLC 6.30% 69,158,354 197,792,892 0 0.00% Senator Investment Group LP 4.19% 46,015,343 131,603,881 -30,579,856 -39.92% BlackRock Fund Advisors 2.74% 30,067,059 85,991,789 +14,171,096 +89.15% Viking Global Investors LP 2.47% 27,084,128 77,460,606 -23,971,016 -46.95% Morgan Stanley Investment Managem... 2.19% 24,038,979 68,751,480 +10,654,526 +79.60% Nikko Asset Management Americas, ... 1.99% 21,858,173 62,514,375 +6,937,185 +46.49% Geode Capital Management LLC 1.10% 12,020,740 34,379,316 +2,220,836 +22.66% Key Data Label Value Exchange NYSE Sector Health Care Industry Biotechnology: Biological Products (No Diagnostic Substances) 1 Year Target $7.00 Today's High/Low $3.855/$3.5 Share Volume 26,606,982 Average Volume N/A Previous Close $3.63 52 Week High/Low $15.864/$2.09 Market Cap 6,253,762,032 P/E Ratio N/A Forward P/E 1 Yr. -30.25 Earnings Per Share(EPS) N/A Annualized Dividend N/A Ex Dividend Date N/A Dividend Pay Date N/A Current Yield N/A CEO: Time: After market Estimate: +/- 15%